Leavitt Chase C.

Leavitt Chase C. serves as the General Counsel and Secretary at Oncternal Therapeutics, Inc., a company focused on developing innovative therapies for cancer treatment. His recent SEC Form 4 filings from January 5, 2024, to February 15, 2024, reveal two public disclosures related to his activities within the firm. The most significant disclosure involved a grant/exercise action valued at approximately $130.4K, highlighting his role in the healthcare sector and the financial activities connected to Oncternal Therapeutics (ONCT).